Thanks To Encouraging Data, These Mid-Cap Stocks Layout $300M Equity Raise

POINT Biopharma Global Inc PNT priced its public offering of 13.9 million shares at $9.00 per share, with gross proceeds of $125 million.
The offer price represents a discount of almost 12% from the last close price of $10.18 on Tuesday.
Underwriters have an option to purchase up to an additional 2.01 million shares.
POINT will use the proceeds to fund clinical and preclinical research and development programs.
Related: POINT Biopharma Shares Jump After Updated Efficacy, Safety Data From Prostate Cancer Candidate.
Akero Therapeutics Inc AKRO commenced an underwritten public offering of $175.0 million.
Underwriters have an option to purchase up to an additional $26.25 million of shares.
Related: Akero Therapeutics Shares More Than Double After Lead NASH Candidate Aces Mid-Stage Study
Price Action: AKRO shares are down 6.51% at $27.16, and PNT shares are down 11.40% at $9.02 on the last check Wednesday.